STOCKHOLM – September 1, 2021 – Martin Ingvar, Member of the Board of ContextVision, has on September 1, 2021 purchased 6,000 shares in ContextVision AB at an average price of NOK 24.41 per share. After the transaction, Mr Ingvar holds a total of 6,000 shares in ContextVision AB. With reference to Section 4-2 of the […]
In the Pan-European multicenter clinical study FirstPath, INIFY Prostate produced highly accurate, robust and homogenous results at all sites
STOCKHOLM – August 31, 2021 – ContextVision, a medical technology software company specializing in image processing, image analysis and decision support tools for digital pathology, today announced that results from FirstPath – a European multicenter clinical study evaluating performance of INIFY® Prostate in routine clinical practice – were presented at the European Congress of Pathology by […]
STOCKHOLM – August 26, 2021 – ContextVision, a medical technology software company specializing in image processing and decision support tools within digital pathology, today announces that the Board of Directors of ContextVision is conducting a review of the company’s structure, and has initiated work assessing a spin-off of the Digital Pathology unit with a goal […]
ContextVision delivered the Company’s best ever second quarter within Medical Imaging. Initial response from the ongoing clinical trials with the Company’s first digital pathology product, INIFY Prostate, are very promising.
Olof Sandén, Chairman of the Board of ContextVision, has on July 6, 2021 purchased 500 shares in ContextVision AB at an average price of NOK 18.00 per share. After the transaction, Mr Sandén holds a total of 3,000 shares in ContextVision AB.
ContextVision announces agreement with two renowned US cancer centers for clinical evaluation of INIFY® Prostate
STOCKHOLM – July 6, 2021 – ContextVision, a medical technology software company specializing in image processing, image analysis and decision support tools for digital pathology, today announced that agreements to conduct a multicenter clinical study of ContextVision’s digital pathology product INIFY® Prostate have been signed with the Ohio State University Comprehensive Cancer Center – Arthur G. […]
On the 5th of May 2021, ContextVision held its ordinary Shareholders’ Annual General Meeting in Stockholm. Due to the extraordinary situation that prevails as a result of the covid-19 pandemic the Annual General Meeting was conducted by advance voting (postal voting) with the support of temporary statutory rules (Sections 20 – 22 of the Act […]
ContextVision today reports its first quarter results for 2021. The quarter saw strong and promising progress within digital pathology and the company’s first product, INIFY Prostate Screening. While the ongoing pandemic slowed sales slightly, solid financials – paired with close dialogues with present and prospective clients – provide a positive outlook.
STOCKHOLM – April 7, 2021 – ContextVision hereby invites shareholders to the Annual General Meeting on May 5, 2021. Please find attached the invitation including agenda and details on how to register and vote. Please contact: for any questions regarding the AGM. For inquiries, please contact CFO Ann-Charlotte LinderothE-mail: About ContextVisionContextVision is a […]
STOCKHOLM – April 7, 2021 – Please find ContextVision’s Annual Report 2020 and Remuneration Report 2020 attached. The reports can also be found on the company’s website: www.contextvision.se Printed copies of the reports will be distributed upon request by e-mail: For inquiries, please contact CFO Ann-Charlotte Linderoth E-mail: About ContextVision ContextVision is […]